ICR discuss Decentralised Clinical Trials

The clinical research landscape is evolving rapidly. Decentralised clinical trials (DCTs) are leading the way toward a more patient-centric and technology-driven future. As traditional methods blend with remote processes, researchers and sponsors must understand these new foundations.

Here are five essential insights into how DCTs are shaping the future of clinical research.

The Future is Decentralised: Are You Ready?

Decentralised clinical trials are changing how we conduct research, making studies more accessible, efficient, and participant-friendly. Here’s what you need to know about this exciting evolution.

What Are Decentralised Clinical Trials (DCTs)?

Decentralised clinical trials, or DCTs, are studies where some or all activities occur away from traditional research sites. Instead of requiring patients to travel, these trials bring the study to the patient. Key activities often include:

  • Virtual consultations via telemedicine.

  • Remote monitoring of vital signs.

  • Home-based participation.

  • Digital data collection through mobile apps.

Trials can be “fully decentralised” or “hybrid,” which combines remote elements with occasional onsite visits.

Now Read: Mastering GCP: Level up Your Skills with Expert ICH GCP Training

2. The Evolution of DCTs: A Rapid Transformation

While decentralised elements have existed for years, the COVID-19 pandemic accelerated their use. Sponsors and regulators collaborated quickly to build emergency frameworks to keep research moving safely. Today, DCTs are no longer just temporary fixes. They are a permanent part of clinical research. Global organizations like the HRA, EMA, and FDA now provide formal guidelines to support their long-term use.

3. Key Technologies Empowering DCTs

Technology is the heart of every successful DCT. These tools help researchers maintain high data integrity while making participation easier for the patient. Essential technologies include:

  • eConsent: Electronic consent forms that patients can sign from home.

  • Wearable Devices: Sensors that track health data in real-time.

  • Telemedicine Platforms: Secure video calls for remote doctor visits.

  • Mobile Engagement Apps: Tools that keep participants informed and compliant.

Note: Accessibility is vital. Researchers must ensure these tools work for all populations, including the elderly and those with visual impairments.

4. Important Considerations When Designing a DCT

Not every study fits a decentralised model. When planning, sponsors must evaluate:

  • Investigational Product (IP): Can the medication be safely delivered and stored at a patient’s home?

  • Patient Safety: Are there robust procedures for remote oversight?

  • Data Integrity: Is the technology platform validated and secure?

  • Contingency Plans: What happens if a patient’s home technology fails?

Successful DCTs require clear protocol instructions and well-trained personnel to manage these complexities.

5. Navigating Regulatory Requirements

Regulators demand that patient safety, rights, and well-being remain the top priority. Compliance is non-negotiable. To succeed, trials must adhere to:

  • ICH E6 (Good Clinical Practice)

  • GDPR (Data Privacy)

  • Rigorous Vendor Validation

Collaborating with patient groups during the design phase ensures the trial is both ethical and relevant.

Join the ICR’s New DCT Special Interest Group (SIG)

The ICR DCT SIG is now formally launched! This Special Interest Group is being led by Stacey Fergusson and Graham Wylie and supported by an enthusiastic, thought-leading organising committee:

  • Janet Messer
  • Katharine Hatton
  • Jo Gambell
  • Davina Calbraith
  • Magda Laskawiec-Szkonter

The team recently held a productive kick-off meeting, and exciting plans are already underway. The first online event will take place in Q2 2025 and will provide a deep dive into the challenges, successes, and lessons learned from the practical implementation of a decentralised clinical trial. More details will be announced soon. In addition, the group is planning further events for 2025, including both online and in-person forums and regional meetings, to explore key topics shaping the future of DCTs.

If you have suggestions for event themes or DCT-related topics, please share them with Stacey Fergusson for inclusion in future SIG planning. We look forward to engaging with you at an upcoming event!

The Future is Decentralised: Are You Ready?

Decentralised clinical trials represent a transformative shift. They make research more accessible, efficient, and participant-friendly. By embracing these five insights, clinical research professionals can stay ahead in this exciting field.

Ready to deepen your understanding of decentralised clinical trials? Join the ICR’s DCT Special Interest Group, subscribe to our newsletter, or attend one of our upcoming webinars. Stay at the forefront of innovation in clinical research with the Institute of Clinical Research (ICR) – visit ICR Global today!

Now Read: The Benefits of Joining the ICR Membership: Unlocking Exclusive Opportunities and Resources